Table 1.

Baseline demographics

	Enadenotucirev monotherapy		Enadenotucirev plus paclitaxel		All patients (N=38)
Characteristic	1×1012 IP (n=7)	6×1012 IP (n=3)	1×1012 IP (n=8)	1×1012 IV (n=20)
Median age, years (min, max)	68 (54, 77)	64 (47, 68)	60 (53, 70)	59 (36, 76)	63 (36, 77)
ECOG performance status
0–1	6 (86)	3 (100)	7 (88)	20 (100)	36 (95)
2	0	0	1 (13)*	0	1 (3)
Missing	1 (14)	0	0	0	1 (3)
Median time from diagnosis to screening, months (min, max)	42.8 (13.7, 90.9)	28.0 (14.9, 50.0)	50.6 (33.9, 109.7)	39.0 (7.2, 278.7)	41.8 (7.2, 278.7)
Histological type
Serous adenocarcinoma	4 (57)	3 (100)	5 (63)	15 (75)	27 (71)
Endometrioid adenocarcinoma	1 (14)	0	0	1 (5)	2 (5)
Other	2 (29)	0	3 (38)	4 (20)	9 (24)
Median (min, max) CA-125 (U/mL)	8750 (93, 29520)	114 (108, 120)	362 (135, 12000)	138 (30, 3958)	151 (30, 29520)
n	3	2	7	17	29
Median (min, max) prior regimens	6 (3, 6)	4 (2, 6)	6 (4, 8)	4 (1, 12)	5 (1, 12)
Prior chemotherapy	7 (100)	3 (100)	8 (100)	20 (100)	38 (100)
Prior paclitaxel	7 (100)	3 (100)	8 (100)	20 (100)	38 (100)
Prior hormonal therapy	2 (29)	1 (33)	2 (25)	4 (20)	9 (24)
Prior monoclonal antibodies	1 (14)	1 (33)	6 (75)†	13 (65)	21 (55)
Prior bevacizumab	1 (14)	1 (33)	6 (75)	12 (60)	20 (53)
Prior ipilimumab	0	0	1 (13)	0	1 (3)
Prior nivolumab	0	0	1 (13)	0	1 (3)
Other	0	0	0	1 (5)	1 (3)
Prior cancer-related surgery	7 (100)	3 (100)	8 (100)	17 (85)	35 (92)
Interval from last taxane-based chemotherapy
<6 months	1 (14)	3 (100)	0	4 (20)	8 (21)
≥6 months	6 (86)	0	8 (100)	16 (80)	30 (79)

Data are n (%) unless specified otherwise.

*One patient had and ECOG performance status of 1 at screening and two at baseline.

†One patient received prior bevacizumab, ipilimumab, and nivolumab.

ECOG, Eastern Oncology Cooperative Group; IP, intraperitoneal; IV, intravenous.